This course has expired. Voir les cours disponibles.
Respirology
Expert Brief 2: Single-inhaler triple therapy vs. multiple-inhaler triple therapy
COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply it to common cases seen in clinical practice.
This program has received an unrestricted educational grant or in-kind support from GSK.
Durée
15 min
Profession
Physician
# des crédits
0.3
Accréditation
Mainpro+
Date d'expiration
2023-09-30
COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply it to common cases seen in clinical practice.
This program has received an unrestricted educational grant or in-kind support from GSK.
La Faculté
John Axler, MD, LMCC, CCFP, FCFP
Andre Belanger, MD, CFPC
Jeff Habert, MD, CCFP, FCFP
Sol Stern, Bsc, MD, MCFP
Objectifs d'apprentissage
Upon completion of this continuing education program, participants will be better able to:
- Determine which patients with COPD could benefit from triple therapy (ICS/LAMA/LABA)
- Contrast the evidence supporting the role of single inhaler triple therapy (SITT) compared to multiple inhaler triple therapy (MITT) in patients with COPD
Accréditation
This self-learning program has been certified by the College of Family Physicians of Canada for up to 0.3 Mainpro+ credits.
This program is developed in collaboration with ICEBM.